Keuangan Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ · Healthcare · Biotechnology · Karyawan: 15.410 · CEO: Leonard S. Schleifer
- Harga
- $927,89 +13,33%
- Kapitalisasi pasar
- $95,5 M
- Nilai perusahaan
- $94,6 M
- Laporan terakhir
- Q3 '26 diajukan 2026-10-30
- Laporan berikutnya
- 2027-01-28 Estimasi EPS: $24,25
Pendapatan (TTM)$16,9 M+18,6% vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)29,5%+3,7 poin vs tahun laluLaba operasional: $4,99 M
Laba bersih (TTM)$4,82 M+5,2% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)$3,59 M-13,6% vs tahun laluCapex: $1,02 M
EPS dilusian (TTM)$45,26+8,4% vs tahun laluJumlah 4 kuartal terakhir
Kas neto$6,59 M+14,9% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $95,5 M EV $94,6 M
- Pendapatan
- $16,9 M 12 bulan terakhir
- Pertumbuhan pendapatan
- +28% Konsensus FY2026
- Margin laba
- 28,5% Laba bersih / pendapatan, TTM
- P/E
- 19,8× Forward 14,4× (FY2026)
- P/S
- 5,7× Harga / penjualan, TTM
- EV / EBITDA
- 15,1× TTM
- Arus kas bebas
- $3,59 M 12 bulan terakhir
- Laba bersih
- $4,82 M 12 bulan terakhir
- Estimasi pendapatan
- $18,4 M Konsensus FY2026
- Laba
- 2027-01-28 Estimasi pendapatan: $5,75 M
- Dividen
- $3,70 Per saham, 12 bulan terakhir
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-10-30): pendapatan melampaui 11,6%, EPS melampaui 21,6%Pendapatan $5,12 M vs $4,58 M yang diharapkan (+11,6%); EPS $20,07 vs $16,51 (+21,6%).
- Pertumbuhan pendapatan menguat: 36,3% yoyPendapatan Q3 '26: $5,12 M, rata-rata empat kuartal sebelumnya: 9,8%.
- Margin operasional 29,5% (TTM), dibanding tahun lalu: +3,7 poinLaba operasional tumbuh 35,3%, pendapatan tumbuh 18,6%.
- 12,2% dari laba sebelum pajak berasal dari non-operasionalLaba sebelum pajak $5,69 M vs laba operasional $4,99 M (TTM). Keuntungan dari kepemilikan saham dan pos sekali-pakai lainnya mengangkat laba bersih dan EPS - laba operasional adalah ukuran bisnis yang lebih bersih.
- Capex: 6,0% dari pendapatan (tahun lalu 6,4%)$1,02 M diinvestasikan dalam 4 kuartal terakhir (+11,2% dibanding tahun sebelumnya). Arus kas bebas: $3,59 M = 74,5% dari laba bersih.
- $3,42 M dikembalikan ke pemegang saham = 95,3% dari arus kas bebasBuyback: $3,04 M (tahun lalu $3,74 M), dividen: $383 jt, kompensasi saham: $1,01 M (TTM).
- Jumlah saham dilusian turun dalam setahun: 1,5%Saham dilusian pada Q3 '26: 106 jt, setahun sebelumnya: 107 jt.
- Kas neto: $6,59 MKas + investasi jangka pendek: $9,3 M, utang termasuk sewa: $2,71 M; tahun lalu kas neto: $5,74 M.
Kuartal terakhir: Q3 '26
Kuartal berakhir 2026-09-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q3 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $5,12 M | $3,75 M | +36,3% |
| Margin kotor | 88,8% | 86,1% | +2,7 poin |
| Laba operasional | $2,05 M | $1,03 M | +99,5% |
| Margin operasional | 40,0% | 27,3% | +12,7 poin |
| Laba bersih | $1,95 M | $1,46 M | +33,5% |
| EPS dilusian | $18,45 | $13,62 | +35,5% |
| Arus kas operasional | $1,78 M | $1,62 M | +10,2% |
| Capex | $300 jt | $201 jt | +49,1% |
| Arus kas bebas | $1,48 M | $1,42 M | +4,6% |
| R&D | $1,82 M | $1,56 M | +16,6% |
| Kompensasi berbasis saham | $256 jt | $237 jt | +7,9% |
Dilaporkan vs konsensus
2026-10-30| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $5,12 M | $4,58 M | +11,6% |
| EPS (basis konsensus) | $20,07 | $16,51 | +21,6% |
Dari laporan 2026-10-30 untuk Q3 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q3 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Collaboration Revenue | $3 M | +52,4% | 58,7% | $9,33 M | +33,9% | |
| Product | $1,81 M | +13,7% | 35,3% | $6,66 M | +0,3% | |
| Product and Service, Other | $310 jt | +56,4% | 6,1% | $913 jt | +41,9% |
Pendapatan per wilayah
porsi dari total| Segmen | Q3 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| United States | $1,1 M | -1,1% | 87,7% | $6,32 M | – | |
| Rest Of World | $154 jt | +5,5% | 12,3% | $815 jt | – |
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- $4,61 M
- Capex
- -$1,02 M
- Buyback
- -$3,04 M
- Dividen
- -$383 jt
- Akuisisi
- -$300 rb
- Utang neto diterbitkan
- $0
- Kompensasi berbasis saham
- $1,01 M
- Arus kas bebas
- $3,59 M
- Dikembalikan ke pemegang saham / FCF
- 95,3%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | 19,8× | 17,0× | 8,3× – 23,7× |
| EV / EBITDA | 15,1× | 14,0× | 6,9× – 20,0× |
| EV / Penjualan | 5,6× | 5,7× | 4,1× – 7,1× |
| Harga / FCF | 26,6× | 18,8× | 10,2× – 25,6× |
| Harga / Nilai buku | 2,8× | 3,2× | 2,6× – 3,6× |
| Imbal hasil FCF | 3,8% | 5,8% | 3,9% – 9,8% |
| Imbal hasil modal yang diinvestasikan | 10,9% | 17,3% | 8,5% – 34,9% |
| Imbal hasil ekuitas | 15,1% | 21,4% | 14,4% – 43,0% |
Analis
Target konsensus $859,63 (-7,4%)
rentang $750,00 – $1.030,00 · peringkat Buy
Beli kuat0
Beli35
Tahan14
Jual0
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $18,4 M | +28,0% | $64,64 | +55,8% | 14,4× | 10 |
| FY2027 | $19,7 M | +7,2% | $67,95 | +5,1% | 13,7× | 9 |
| FY2028 | $21,3 M | +8,1% | $75,38 | +10,9% | 12,3× | 7 |
| FY2029 | $22,9 M | +7,6% | $82,91 | +10,0% | 11,2× | 2 |
| FY2030 | $24,5 M | +6,8% | $89,99 | +8,5% | 10,3× | 4 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 218 angka yang ditandai Regeneron Pharmaceuticals, Inc. dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable and Accrued Liabilities, Current | $2,88 M2025-12-31 | $2,53 M | +13,8% | $2,88 M | $2,53 M | +13,8% |
| Accounts Payable, Current | $1,14 M | $904 jt | +26,2% | $939 jt | $790 jt | +18,9% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $7,58 M | $5,69 M | +33,3% | $5,74 M | $6,21 M | -7,6% |
| Accrued Liabilities and Other Liabilities | $3,59 M | $2,98 M | +20,7% | $2,88 M | $2,53 M | +13,8% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$198 jt | $69 jt | -386,2% | $77,5 jt | -$7,9 jt | +1.081,0% |
| Additional Paid in Capital | $15,2 M | $13,8 M | +10,0% | $14 M | $12,9 M | +8,9% |
| Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities | -$165 jt | $159 jt | -204,2% | $474 jt | $7,9 jt | +5.900,0% |
| Amortization of Intangible Assets | – | – | – | $179 jt | $129 jt | +38,7% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $247 jt | $241 jt | +2,6% | $1 M | $997 jt | +0,5% |
| Assets | $44,4 M | $40,2 M | +10,5% | $40,6 M | $37,8 M | +7,4% |
| Assets, Current | $20,8 M | $18 M | +15,7% | $18 M | $18,7 M | -3,4% |
| Assets, Fair Value Disclosure | $17,8 M | – | – | $17,9 M | $16,9 M | +5,9% |
| Business Combination, Contingent Consideration, Liability | $10,3 jt2025-12-31 | $52,3 jt | -80,3% | $10,3 jt | $52,3 jt | -80,3% |
| Capital Expenditures Incurred but Not yet Paid | $41,6 jt | $50,8 jt | -18,1% | $179 jt | $152 jt | +17,9% |
| Cash and Cash Equivalents, at Carrying Value | $3,66 M | $2,51 M | +46,0% | $3,12 M | $2,49 M | +25,3% |
| Cash and Cash Equivalents, Fair Value Disclosure | $2,64 M | – | – | $2,12 M | $1,45 M | +46,1% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $3,67 M | $2,51 M | +46,1% | $3,12 M | $2,49 M | +25,5% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $1,21 M | $498 jt | +142,3% | $635 jt | -$249 jt | +355,1% |
| Common Stock, Dividends, Per Share, Declared | $0,94 | $0,88 | +6,8% | – | – | – |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $1,79 M | $1,48 M | +21,0% | $4,59 M | $4,49 M | +2,3% |
| Contract with Customer, Liability, Current | $750 jt | $546 jt | +37,4% | $553 jt | $628 jt | -11,9% |
| Contract with Customer, Liability, Noncurrent | $220 jt | $219 jt | +0,5% | $209 jt | $186 jt | +12,4% |
| Costs and Expenses | $3,07 M | $2,73 M | +12,5% | $10,8 M | $10,2 M | +5,4% |
| Current Federal Tax Expense (Benefit) | – | – | – | $1,01 M | $1,09 M | -7,3% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $479 jt | $43,1 jt | +1.011,6% |
| Current Income Tax Expense (Benefit) | – | – | – | $1,51 M | $1,12 M | +34,4% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $19,8 jt | -$11,1 jt | +278,4% |
| Debt Securities, Available-for-sale | $15 M | $15,5 M | -3,2% | $15,7 M | $14,3 M | +9,7% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $4 jt | $93,2 jt | -95,7% | $98,5 jt | $30,1 jt | +227,2% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $168 jt | $6 jt | +2.698,3% | $2,5 jt | $39 jt | -93,6% |
| Debt Securities, Available-for-sale, Amortized Cost | $15,2 M | $15,4 M | -1,6% | $15,6 M | $14,3 M | +8,9% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer | $573 jt2025-09-30 | $1,67 M | -65,6% | $1,22 M2024-12-31 | $4,16 M | -70,7% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss | $4 jt2025-09-30 | $25,2 jt | -84,1% | $18 jt2024-12-31 | $107 jt | -83,1% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months | $13,9 M2025-09-30 | $12,3 M | +12,6% | $12,2 M2024-12-31 | $7,85 M | +55,1% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss | $2 jt2025-09-30 | $800 rb | +150,0% | $21 jt2024-12-31 | $9 jt | +133,3% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $9,38 M | $9,52 M | -1,5% | $10,2 M | $7,8 M | +31,0% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | $5,64 M | $5,94 M | -5,0% | $5,49 M | $6,52 M | -15,9% |
| Debt Securities, Available-for-sale, Unrealized Loss Position | $14,5 M2025-09-30 | $14 M | +3,3% | $13,4 M2024-12-31 | $12 M | +11,5% |
| Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | $6 jt2025-09-30 | $26 jt | -76,9% | $39 jt2024-12-31 | $116 jt | -66,3% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | -$845 jt | -$936 jt | +9,7% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $75,3 jt | $183 jt | -58,9% |
| Deferred Income Tax Assets, Net | $4,54 M | $3,85 M | +17,9% | $4,08 M | $3,31 M | +23,0% |
| Deferred Income Tax Expense (Benefit) | – | – | – | -$785 jt | -$757 jt | -3,7% |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | -$15,5 jt | -$4,9 jt | -216,3% |
| Deferred Tax Assets, Gross | $4,08 M2025-12-31 | $3,41 M | +19,7% | $4,08 M | $3,41 M | +19,7% |
| Deferred Tax Assets, Net | $4,08 M2025-12-31 | $3,31 M | +23,0% | $4,08 M | $3,31 M | +23,0% |
| Deferred Tax Assets, Other | $49,9 jt2025-12-31 | $43 jt | +16,0% | $49,9 jt | $43 jt | +16,0% |
| Deferred Tax Assets, Property, Plant and Equipment | $193 jt2025-12-31 | $145 jt | +32,7% | $193 jt | $145 jt | +32,7% |
| Deferred Tax Assets, Tax Credit Carryforwards | $79,6 jt2025-12-31 | $84,1 jt | -5,4% | $79,6 jt | $84,1 jt | -5,4% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | $452 jt2025-12-31 | $420 jt | +7,7% | $452 jt | $420 jt | +7,7% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | $159 jt2025-12-31 | $185 jt | -14,2% | $159 jt | $185 jt | -14,2% |
| Deferred Tax Liabilities, Unrealized Gains on Trading Securities | $1,9 jt2025-12-31 | $93 jt | -98,0% | $1,9 jt | $93 jt | -98,0% |
| Defined Contribution Plan, Cost | – | – | – | $95,7 jt | $90,2 jt | +6,1% |
| Depreciation, Depletion and Amortization | $121 jt | $137 jt | -11,5% | $544 jt | $483 jt | +12,6% |
| Dividends, Common Stock | $98,3 jt | $93,4 jt | +5,2% | $377 jt | – | – |
| Earnings Per Share, Basic | $19,16 | $14,09 | +36,0% | $43,07 | $40,90 | +5,3% |
| Earnings Per Share, Diluted | $18,45 | $13,62 | +35,5% | $41,48 | $38,34 | +8,2% |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $500 rb | -$400 rb | +225,0% | $300 rb | -$700 rb | +142,9% |
| Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | – | – | – | $1,1 M | – | – |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | – | – | – | 21,0% | 21,0% | 0,0% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, estimasi: Financial Modeling Prep. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data per 2026-11-01